Check point inhibitor
Showing 1 - 25 of >10,000
Physical Activity and Exercise in Cancer Immunotherapy Treatment
Not yet recruiting
- Cancer
- Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions
- (no location specified)
Nov 22, 2023
Acral Melanoma, Mucosal Melanoma Trial in Seoul (Pembrolizumab, Vactosertib)
Not yet recruiting
- Acral Melanoma
- Mucosal Melanoma
- Pembrolizumab, Vactosertib
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Jun 23, 2022
Breast Cancer, Metastatic Breast Cancer, Breast Tumor Trial in Port Jefferson Station (SV-BR-1-GM, Cyclophosphamide, Interferon
Not yet recruiting
- Breast Cancer
- +4 more
- SV-BR-1-GM
- +4 more
-
Port Jefferson Station, New YorkNew York Cancers & Blood Specialists
Oct 2, 2023
Locally Advanced Head Neck Cancer Trial in Kuwait (Pembrolizumab)
Recruiting
- Locally Advanced Head and Neck Cancer
-
Kuwait, KuwaitKuwait Cancer Control Center
Apr 13, 2021
Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma Trial in Jerusalem
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Pembrolizumab
-
Jerusalem, IsraelSharett institute, Hadassah University Hospital - Ein-Kerem
Nov 8, 2021
Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic
Not yet recruiting
- Advanced Solid Tumor
- +4 more
- Cadonilimab
- Stereotactic body radiotherapy
-
Peking, Beijing, ChinaDepartment of radiation oncology, Peking University Third Hospit
Jun 20, 2023
Squamous Cell Head and Neck Carcinoma Trial (Durvalumab, radiotherapy, Placebo)
Withdrawn
- Squamous Cell Head and Neck Carcinoma
- Durvalumab
- +3 more
- (no location specified)
May 6, 2021
Glioblastoma, Adult Trial in Worldwide (Multiple dose of EO2401)
Recruiting
- Glioblastoma, Adult
- Multiple dose of EO2401
-
Boston, Massachusetts
- +9 more
Dec 7, 2021
Adverse Events in Patients Treated With Immune Check Point
Recruiting
- Immune-related Adverse Event
- Antiinflammatory/DMARDs
-
Kristiansand, Norway
- +4 more
Sep 15, 2022
Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France
Not yet recruiting
- Metastatic Renal Cell Carcinoma
- Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
- Combination PD-1/PD-L1 ICI + VEGFR-TKI
- Treatment pause
-
Bayonne, France
- +24 more
Aug 10, 2022
CaboCHECK - Cabozantinib in Adult Advanced Renal Cell Carcinoma
Terminated
- Advanced Renal Cell Carcinoma (All Subtypes)
- Metastatic Renal Cell Carcinoma (All Subtypes)
- Documentation
-
Essen, Nordrhein-Westfalen, Germany
- +1 more
Dec 21, 2022
Point of Care Device to Measure HbA1c
Not yet recruiting
- Pregnant
- Postpartum
- Point of care device to measure HbA1c
- (no location specified)
Feb 10, 2023
Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body
Recruiting
- Sarcoma
- +2 more
- Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University, School of Medici
Oct 3, 2023
NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))
Withdrawn
- NSCLC Stage IV
- combination regimen tremelimumab /durvalumab
- platinum-based chemotherapy (SoC)
-
Gauting, GermanyAsklepios Fachkliniken München-Gauting
Sep 26, 2022
The Status of Immune Checkpoints at Gastrointestinal Cancer
Completed
- Gastrointestinal Cancer
- Flow cytometric analysis
-
Istanbul, TurkeyIstanbul Training and Reseach Hospital
Dec 4, 2022
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab, pemetrexed, platinum
- Osimertinib
-
Peking, ChinaPeking Union Medical College Hospital
Nov 16, 2023
Multiple Myeloma, Lymphoma Trial in Washington, Hackensack (Ipilimumab, Nivolumab)
Active, not recruiting
- Multiple Myeloma
- Lymphoma
-
Washington, District of Columbia
- +1 more
Dec 2, 2021
Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors Trial in Baltimore (APA, Sham APA control,
Completed
- Aromatase Inhibitor
- +2 more
- APA
- +2 more
-
Baltimore, MarylandJohns Hopkins School of Nursing
Jul 27, 2021
Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)
Not yet recruiting
- Cervical Cancer
- Anti-PD-1 antibody balstilimab
-
Amsterdam, NetherlandsAmsterdam UMC
Oct 17, 2023
Checkpoint Inhibitor Response
Active, not recruiting
- NSCLC
- +4 more
- Breathprint analysis and patient-reported outcomes
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Feb 24, 2022
Migraine Trial in United States (AXS-07 (meloxicam-rizatriptan))
Recruiting
- Migraine
- AXS-07 (meloxicam-rizatriptan)
-
Colton, California
- +18 more
Sep 19, 2022
Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma Trial in Worldwide (EO2401)
Recruiting
- Adrenocortical Carcinoma
- +2 more
- EO2401
-
Houston, Texas
- +9 more
Dec 7, 2021
Serial PET MPI in Patients Undergoing Cancer Treatment
Enrolling by invitation
- Cancer
- +3 more
-
Los Angeles, CaliforniaWest Los Angeles VA Medical Center
Jun 12, 2023
Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover
Not yet recruiting
- Metastatic Melanoma
- +2 more
- Lifileucel plus Pembrolizumab
- Pembrolizumab with Optional Crossover Period
- (no location specified)
Feb 13, 2023